HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
STAT3
signal transducer and activator of transcription 3
Chromosome 17 Β· 17q21.2
NCBI Gene: 6774Ensembl: ENSG00000168610.17HGNC: HGNC:11364UniProt: A0A7I2V395
3,704PubMed Papers
22Diseases
1Drugs
100Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub GeneTranscription Factor
RESEARCH IMPACT
Highly StudiedLandmark GeneTrendingVariant-Rich
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
growth hormone receptor signaling pathwayRNA sequestering activityregulation of DNA-templated transcriptionprotein import into nucleusautoimmune diseaseAutosomal dominant hyper-IgE syndromehyper-IgE recurrent infection syndrome 1, autosomal dominanthyper-IgE syndrome
✦AI Summary

STAT3 is a transcription factor that serves as a key signal transducer for cellular responses to cytokines and growth factors 1. Upon activation by JAK-coupled receptors, STAT3 is phosphorylated, translocates to the nucleus, and recruits coactivators such as NCOA1 and MED1 to target gene promoters 2. STAT3 regulates diverse cellular processes including cell cycle progression, immune cell differentiation (promoting Th17 and regulatory T cell development), and inflammatory responses 1. In cancer, STAT3 promotes multiple hallmark features including proliferation, metastasis, angiogenesis, and immunosuppression through downstream targets like VEGFA and CCND1 34. STAT3 activity is tightly regulated through post-translational modifications including phosphorylation, acetylation, methylation, and ubiquitination, which modulate its stability and transcriptional activity 52. Beyond cancer, STAT3 plays critical roles in liver fibrosis pathogenesis, cardiac hypertrophy (where deubiquitination by USP20 provides cardioprotection), and pulmonary fibrosis by facilitating myofibroblast differentiation through super enhancer formation 67. Dysregulated STAT3 signaling is associated with autoimmune diseases and hyper-IgE syndrome, highlighting its importance in immune homeostasis. STAT3 represents a promising therapeutic target across multiple disease contexts.

Sources cited
1
STAT3 regulates genes involved in cell cycle, cell survival, immune response, and its antagonistic relationship with STAT1 determines inflammatory versus anti-inflammatory responses
PMID: 32987855
2
STAT3 is involved in cancer hallmarks including proliferation, metastasis, angiogenesis, immunosuppression, and represents a promising therapeutic target
PMID: 38245798
3
STAT3 is closely related to liver fibrosis pathogenesis and can play pro- or anti-inflammatory roles in various liver diseases
PMID: 32702499
4
STAT3 activation leads to increased expression of VEGFA and CCND1, promoting cancer cell proliferation and metastasis
PMID: 38001065
5
STAT3 can be methylated at arginine 729, which regulates its membrane localization and interaction with JAK2 in breast cancer metastasis
PMID: 37813837
6
USP20 deubiquitinates STAT3, reducing its phosphorylation and nuclear translocation, thereby protecting against cardiac hypertrophy
PMID: 40192103
7
STAT3 facilitates super enhancer formation and H3K27ac modification to promote fibroblast-to-myofibroblast differentiation in pulmonary fibrosis
PMID: 40464702
Disease Associationsβ“˜22
autoimmune diseaseOpen Targets
0.84Strong
Autosomal dominant hyper-IgE syndromeOpen Targets
0.78Strong
hyper-IgE recurrent infection syndrome 1, autosomal dominantOpen Targets
0.75Strong
hyper-IgE syndromeOpen Targets
0.69Moderate
hyper-IgE syndrome 6, autosomal dominant, with recurrent infectionsOpen Targets
0.67Moderate
cancerOpen Targets
0.63Moderate
STAT3 gain of functionOpen Targets
0.55Moderate
Crohn's diseaseOpen Targets
0.51Moderate
diffuse large B-cell lymphomaOpen Targets
0.49Moderate
neurodegenerative diseaseOpen Targets
0.49Moderate
immunodeficiency diseaseOpen Targets
0.47Moderate
leukemiaOpen Targets
0.47Moderate
multiple sclerosisOpen Targets
0.46Moderate
lymphoid neoplasmOpen Targets
0.46Moderate
autoimmune disease, multisystem, infantile-onsetOpen Targets
0.46Moderate
genetic disorderOpen Targets
0.45Moderate
ulcerative colitisOpen Targets
0.44Moderate
inflammatory bowel diseaseOpen Targets
0.43Moderate
ebv-positive nodal t- and nk-cell lymphomaOpen Targets
0.42Moderate
T-cell large granular lymphocyte leukemiaOpen Targets
0.40Weak
Autoimmune disease, multisystem, infantile-onset, 1UniProt
Hyper-IgE syndrome 1, autosomal dominant, with recurrent infectionsUniProt
Pathogenic Variants100
NM_139276.3(STAT3):c.1003C>T (p.Arg335Trp)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|not provided|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant
β˜…β˜…β˜†β˜†2025β†’ Residue 335
NM_139276.3(STAT3):c.1145G>A (p.Arg382Gln)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function|Inherited Immunodeficiency Diseases|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 382
NM_139276.3(STAT3):c.1909G>A (p.Val637Met)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|not provided|Hyper-IgE syndrome|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function
β˜…β˜…β˜†β˜†2025β†’ Residue 637
NM_139276.3(STAT3):c.1970A>G (p.Tyr657Cys)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 657
NM_139276.3(STAT3):c.1397A>G (p.Asn466Ser)Pathogenic
not provided|Hyper-IgE recurrent infection syndrome 1, autosomal dominant
β˜…β˜…β˜†β˜†2025β†’ Residue 466
NM_139276.3(STAT3):c.1268G>A (p.Arg423Gln)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|STAT3-related early-onset multisystem autoimmune disease|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function
β˜…β˜…β˜†β˜†2025β†’ Residue 423
NM_139276.3(STAT3):c.2144C>T (p.Pro715Leu)Pathogenic
not provided|Inborn genetic diseases|Inherited Immunodeficiency Diseases|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3-related early-onset multisystem autoimmune disease|STAT3-related early-onset multisystem autoimmune disease|STAT3-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 715
NM_139276.3(STAT3):c.2125A>G (p.Lys709Glu)Likely pathogenic
not provided|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function
β˜…β˜…β˜†β˜†2025β†’ Residue 709
NM_139276.3(STAT3):c.1144C>T (p.Arg382Trp)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|not provided|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function|STAT3-related early-onset multisystem autoimmune disease|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3-related early-onset multisystem autoimmune disease
β˜…β˜…β˜†β˜†2025β†’ Residue 382
NM_139276.3(STAT3):c.1261G>A (p.Gly421Arg)Pathogenic
STAT3-related early-onset multisystem autoimmune disease|not provided|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant|Hyper-IgE recurrent infection syndrome 1, autosomal dominant|STAT3-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 421
NM_139276.3(STAT3):c.2147C>T (p.Thr716Met)Pathogenic
STAT3-related early-onset multisystem autoimmune disease|not provided|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant|See cases
β˜…β˜…β˜†β˜†2025β†’ Residue 716
NM_139276.3(STAT3):c.1165A>G (p.Thr389Ala)Likely pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 389
NM_139276.3(STAT3):c.832C>T (p.Arg278Cys)Likely pathogenic
not provided|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function
β˜…β˜…β˜†β˜†2025β†’ Residue 278
NM_139276.3(STAT3):c.994C>T (p.His332Tyr)Pathogenic
not provided|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function|Hyper-IgE recurrent infection syndrome 1, autosomal dominant
β˜…β˜…β˜†β˜†2025β†’ Residue 332
NM_139276.3(STAT3):c.2117T>C (p.Leu706Pro)Pathogenic
not provided|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant
β˜…β˜…β˜†β˜†2025β†’ Residue 706
NM_139276.3(STAT3):c.1863C>A (p.Phe621Leu)Pathogenic
not provided|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant
β˜…β˜…β˜†β˜†2025β†’ Residue 621
NM_139276.3(STAT3):c.1979T>C (p.Met660Thr)Pathogenic
not provided|Hyper-IgE syndrome|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function
β˜…β˜…β˜†β˜†2024β†’ Residue 660
NM_139276.3(STAT3):c.454C>T (p.Arg152Trp)Pathogenic
STAT3-related early-onset multisystem autoimmune disease|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 152
NM_139276.3(STAT3):c.1780G>A (p.Glu594Lys)Likely pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|STAT3 gain of function;Hyper-IgE recurrent infection syndrome 1, autosomal dominant
β˜…β˜…β˜†β˜†2024β†’ Residue 594
NM_139276.3(STAT3):c.1384GTG[1] (p.Val463del)Pathogenic
Hyper-IgE recurrent infection syndrome 1, autosomal dominant|not provided|Hyper-IgE recurrent infection syndrome 1, autosomal dominant;STAT3 gain of function
β˜…β˜…β˜†β˜†2022β†’ Residue 463
View on ClinVar β†—
Drug Targets1
DANVATIRSENPhase II
STAT-3 mRNA 3'UTR antisense inhibitor
head and neck squamous cell carcinoma
Related Genes
TP53Protein interaction100%TYK2Protein interaction100%BCL2Protein interaction100%CEBPBProtein interaction100%CREB1Protein interaction100%EGR1Protein interaction100%
Tissue Expression6 tissues
Lung
100%
Liver
93%
Ovary
44%
Heart
38%
Brain
38%
Bone Marrow
32%
Gene Interaction Network
Click a node to explore
STAT3TP53TYK2BCL2CEBPBCREB1EGR1
PROTEIN STRUCTURE
Preparing viewer…
PDB6NJS Β· 2.70 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.11Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.06 [0.03–0.11]
RankingsWhere STAT3 stands among ~20K protein-coding genes
  • #11of 20,598
    Most Researched3,704 Β· top 1%
  • #769of 5,498
    Most Pathogenic Variants100 Β· top quartile
  • #83of 17,882
    Most Constrained (LOEUF)0.11 Β· top 1%
Genes detectedSTAT3
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
Redox Regulation of STAT1 and STAT3 Signaling.
PMID: 32987855
Int J Mol Sci Β· 2020
1.00
2
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
PMID: 38245798
J Exp Clin Cancer Res Β· 2024
0.90
3
Crosstalk between circular RNAs and the STAT3 signaling pathway in human cancer.
PMID: 39121909
Biochim Biophys Acta Gene Regul Mech Β· 2024
0.88
4
A STAT3/integrin axis accelerates pancreatic cancer initiation and progression.
PMID: 40701148
Cell Rep Β· 2025
0.82
5
The pulmonary effects of STAT3 deficiency.
PMID: 37331431
J Allergy Clin Immunol Β· 2023
0.80